LSD Therapy

A groundbreaking study conducted by researchers from Spain’s Universidad de las Palmas de Gran Canaria has shown that low-dose LSD may provide a safe and effective treatment for dogs suffering from anxiety. This independent study, published in Veterinary Research Communications, is the first...

Welcome to a new episode of the Benzinga Psychedelics Podcast where we’re joined by Robert Barrow, CEO of Mind Medicine (MindMed) (NASDAQ:MNMD), which has taken the development of LSD-based therapy to new heights. The biopharma company recently obtained a "breakthrough therapy" designation...

Shortly following the news on FDA's "breakthrough therapy" designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed (NASDAQ:MNMD) announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per...

Mind Medicine (MindMed) (NASDAQ:MNMD) announced that the FDA has granted the "breakthrough therapy" designation to its MM120 (lysergide d-tartrate) program for the treatment of Generalized Anxiety Disorder (GAD).  The clinical-stage psychedelics biotech firm will now join industry counterparts...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) announced its financial results for the year ended December 31, 2023 along with a business update. Numbers: Cash and cash equivalents totaled $99.7 million by Dec. 31, 2023, an almost 30% reduction compared to the $142.1 million held by December 31, 2022...

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024. Clinical Development: Present...

A newly published analysis of Federico Fellini's films explores how LSD therapy would have fueled the famed Italian filmmaker’s creative process regarding time, space, body and perception of the self. See Also: Dua Lipa Interviews 'Queen Of Psychedelics' Amanda...

Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S. patent application covering the composition of matter, treatment uses and a novel production method of non-hallucinogenic LSD derivatives including the company’s 2-bromo-LSD derivative BETR-001...

Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b study on proprietary LSD compound MM-120 (lysergide D-tartrate) for General Anxiety Disorder (GAD.)...

The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis the upcoming management elections this June 15. MindMed recently...

MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.  “We have seen a meaningful acceleration in enrollment over the last few months since our full set of study sites were...

Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business highlights. Numbers show: Cash and cash equivalents totaled $129.4 million as of March 31, an...

Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of...

A recent study published in the British Journal of Pharmacology looked into how psychedelics like LSD can affect the biological endocannabinoid system, otherwise targeted by cannabis compounds, which directly bind to cannabinoid receptors. See also: Pot Smoking Baby Boomers Are On The...

LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon The Beckley Foundation and its founder Amanda Feilding announced a new research program with King's College London and UCL on the effects of full dose LSD as well as a...